The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00265-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Viktória Szél und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology, Budapest, Hungary. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Isoniazid, Antitubercular Agents, Bacterial Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, German Ministry of Health, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Thirteen commercial genotypic antimicrobial susceptibility assays interrogate mutations upstream of ahpC to infer isoniazid resistance for Mycobacterium tuberculosis . We demonstrate that relying on one of these compensatory mutations (i.e., ahpC c−54t)—rather than causative resistance mutations in katG that ahpC compensates for—can result in systematic false-resistant results for isoniazid with the Cepheid Xpert MTB/XDR and suboptimal treatment. The WHO mutation catalog should be refined to address this scenario.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Reference Laboratory for Mycobacteriology, National Koranyi Institute of Pulmonology, Budapest, Hungary.
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- End TB Dx Consulting LLC, San Diego, California, USA.
- DLD IVD Consulting LLC, Medway, Massachusetts, USA.
- Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
- German Center for Infection Research, Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
ORCID-Profile: Jody E Phelan, Sophia B Georghiou, Taane G Clark, Stefan Niemann, Claudio U Köser
Förderung
- UK Research and Innovation
- German Ministry of Health
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Szél, V., Phelan, J. E., Georghiou, S. B., Dolinger, D. L., Clark, T. G., Niemann, S., Lőrinczi, L. K., & Köser, C. U. (2025). The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00265-25
Vancouver
Szél V, Phelan JE, Georghiou SB, Dolinger DL, Clark TG, Niemann S, et al. The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00265-25
BibTeX
@article{Szl2025,
author = {Szél, Viktória and Phelan, Jody E and Georghiou, Sophia B and Dolinger, David L and Clark, Taane G and Niemann, Stefan and Lőrinczi, Lilla K and Köser, Claudio U},
title = {The ahpC c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00265-25}
}
EUVIMED